[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Micocci et al., 2024 - Google Patents

Synthesis of fluorinated curcumin derivatives for detecting amyloid plaques by 19 F-MRI

Micocci et al., 2024

View HTML
Document ID
15144934899707970118
Author
Micocci S
Stefania R
Garello F
Fasoglio U
Hawala I
Tei L
Crich S
Digilio G
Publication year
Publication venue
Organic & Biomolecular Chemistry

External Links

Snippet

The most prominent pathophysiological hallmark of Alzheimer's disease is the aggregation of amyloid-β (Aβ) peptides into senile plaques. Curcumin and its derivatives exhibit a high affinity for binding to Aβ fibrils, effectively inhibiting their growth. This property holds promise …
Continue reading at pubs.rsc.org (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Similar Documents

Publication Publication Date Title
US11020493B2 (en) Double-labeled probe for molecular imaging and use thereof
Boros et al. Gd (DOTAla): a single amino acid Gd-complex as a modular tool for high relaxivity MR contrast agent development
JP6542748B2 (en) CEST system showing concentration-independent response
RU2561718C2 (en) Manganese chalates and use thereof as contrast agents in magnetic resonance imaging (mri)
US8986657B2 (en) Methods and system for detecting soluble amyloid-β
US10759817B2 (en) Gadolinium complex, method for synthesis of the gadolinium complex, and MRI contrast agent including the gadolinium complex
CN102137849A (en) Cyclic polyamines for binding phosphatidylserine
AU2018373675A1 (en) A double-labeled probe for molecular imaging and use thereof
JP2023145464A (en) Double-labeled probe for molecular imaging and use thereof
Tripepi et al. Synthesis of high relaxivity gadolinium AAZTA tetramers as building blocks for bioconjugation
CN105939732A (en) Molecular imaging probes
EP3551614B1 (en) Dimeric contrast agents
CN107949383B (en) Amyloid binding agents containing nitroxide compounds for imaging
AU2016289474A1 (en) HBED-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents
KR102515879B1 (en) Novel gadolinium-based compound, method for the preparation thereof, and mri contrast agent comprising the same
US20070202047A1 (en) Polyamine-substituted ligands for use as contrast agents
US20020052354A1 (en) Paramagnetic DOTA derivatives, pharmaceutical agents that contain the latter, process for their production, and their use for MR imaging of necrosis and infarction
Goswami et al. Synthesis, relaxation properties and in vivo assessment of a carborane-GdDOTA-monoamide conjugate as an MRI blood pool contrast agent
Micocci et al. Synthesis of fluorinated curcumin derivatives for detecting amyloid plaques by 19 F-MRI
WO2013184678A1 (en) Molecular probes for multimodality imaging of anionic membrane surfaces
US20230094602A1 (en) Novel gadolinium-based compound, preparation method therefor, and mri contrast agent containing same
US20230233714A1 (en) Novel gadolinium-based compound, method for producing same, and mri contrast agent containing same
Lin et al. In vivo MR/optical imaging for gastrin releasing peptide receptor of prostate cancer tumor using Gd-TTDA-NP-BN-Cy5. 5
KR102683452B1 (en) Gadolinium-based compound, mri contrast agent comprising the same
KR102659248B1 (en) Gadolinium-based compound, mri contrast agent comprising the same